Pibrentasvir

Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral Hepatitis B Virus RNA Destabilizer, at the International Liver Congress™ 2021 Sponsored by the European Association for the Study of the Liver

Retrieved on: 
Thursday, June 3, 2021
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious diseases, Clinical trials, Science, Biotechnology, FDA, Other Science, Health, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Glecaprevir/pibrentasvir, Infectious causes of cancer, Glecaprevir, Hepatitis C, AbbVie, Human metapneumovirus, Pibrentasvir

Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
  • Enantas research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir).

Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 11, 2021
Research, Infectious diseases, Clinical trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Chemical compounds, Organic compounds, Chemistry, Carbamates, Healthcare-associated infections, Pneumoviridae, Glecaprevir/pibrentasvir, Glecaprevir, Hepatitis C, Pibrentasvir, Human metapneumovirus, AbbVie

Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).

Key Points: 
  • Enanta\xe2\x80\x99s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH).
  • Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).\nEnanta\xe2\x80\x99s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie.
  • Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET\xc2\xae (U.S.) and MAVIRET\xc2\xae (ex-U.S.) (glecaprevir/pibrentasvir).
  • Please visit www.enanta.com for more information.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210511005247/en/\n'

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

Retrieved on: 
Monday, November 23, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Chemical compounds, Organic compounds, Chemistry, Carbamates, Infectious causes of cancer, Hepatitis C, Glecaprevir, Pibrentasvir, AbbVie, BlackBerry Limited

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2020.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fourth quarter and year ended September 30, 2020.
  • FISCAL FOURTH QUARTER AND YEAR ENDED SEPTEMBER 30, 2020 FINANCIAL RESULTS
    Total revenue of $23.6 million for the three months ended September 30, 2020 consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET (glecaprevir/pibrentasvir).
  • Research and development expenses were $36.7 million for the three months ended September 30, 2020, compared to $38.7 million for the three months ended September 30, 2019.
  • For the twelve months ended September 30, 2020, research and development costs were $136.8 million compared to $142.2 million in 2019.

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

Retrieved on: 
Wednesday, May 6, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Chemical compounds, Chemistry, Organic compounds, Carbamates, Cyclopropanes, Glecaprevir/pibrentasvir, Glecaprevir, Hepatitis C, Pibrentasvir, AbbVie Inc., Pharmaceutical industry in India

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2020.

Key Points: 
  • Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal second quarter ended March 31, 2020.
  • With these catalysts in mind, we continue to monitor any impact of COVID-19 on all of our clinical studies.
  • Fiscal Second Quarter Ended March 31, 2020 Financial Results
    Total revenue for the three months ended March 31, 2020 was $27.6 million and consisted of royalty revenue derived primarily from worldwide net sales of AbbVies hepatitis C virus (HCV) regimen MAVYRET/MAVIRET (glecaprevir/pibrentasvir).
  • May 19, 2020 RBC Capital Markets Global Healthcare Conference, Virtual
    June 18, 2020 Raymond James Healthcare Conference, Virtual
    Enanta plans to issue its fiscal third quarter financial results press release, and hold a conference call regarding those results, on August 4, 2020.